#2 in sale of inhalers globally
Respiratory 22% share in total revenues
Foracort #10 among 4 @Cipla_Global brands that featured in top 50 brands in India
46% in MDIs & 65% in FPSM pMDI Mkt share in S Africa
![](https://pbs.twimg.com/media/EgBQDeDU0AACtEj.jpg)
Scaling up supply of Lopinavir+Ritonavir,HCQ,Azithromycin
Partnered with @Roche for #tocilizumab
Partnered with @GileadSciences for #remdesivir to manufacture & market in 127 countries
With CSIR-IICT for #favipiravir
$1bn orgnizatn,40% of revenue
Leadership in respiratory,urology,anti-virals
Launched foracort syncobreathe
Acquired brand & trademark for Vysov&Vysov M
Deal for Omalizumab(Allergic Asthma)with Reliance lifesciences
Stempeucel used in DM
Acq 4nutraceuticals
Mkt share in CNS 13%,RS 11%,GIS 8%
1 out of 4 patients use @Cipla_Global OTC products
1 in 4 patient is on Ciplas triple therapy(ARV)
Joint dvlpmnt Quadrimune,4 in1 paediatric HIV drug
Partnered with @AstraZeneca & luye pharma for Quetiapine bipolar disorders
![](https://pbs.twimg.com/media/EgBagKkU0AEE36M.jpg)
![](https://pbs.twimg.com/media/EgBagZLVoAAG5dA.jpg)
![](https://pbs.twimg.com/media/EgBaglDUMAANTNp.jpg)
![](https://pbs.twimg.com/media/EgBag0oU4AAXZQW.jpg)
AR 2019-20
Capacity 2019-20
Billion(bn) Million(mn)
34 bn units of tablets & capsules
8.6mn units of lyophilised injection
29.9 mn units of nasal spray
2.5 mn units of form fill seal eye drops
109.6 mn units of aerosol pMDI
808 mn repsules
93 mn oral liquids
1) EU - Geftinib tabs,Fluticasone propionate MDI,FPSM MDI,Mometasone nasal spray
2)US Budesonide capsule,Metoprolol ER,Pregabalin caps,Esomeprazole
3)SAfrica- Dolutegravir,Tenofovir,Lamivudine tabs
4) India - Formoterol fumarate dihydrate& Budesonide aersol
Ciplas Fluticasone propionate & Salmeterol inhalation powder ,generic version for Advair ,for asthma patients in 1st attempt
Study done over 100 sites in the USA,enrolled 1400 patients
1) Zemdri(Plazomicin)
from Achaogen,once daily IV Aminoglycoside for complicated Urinary infections
2)IV Tramadol
In 2018 invested in Avenue therapeutics for pain management
3)Elores - acq from venus remedies,Antibiotic resistance breaker in Infection
4 in 1 treatment for HIV positive children available in granular form for easy administration in children
Also can be stored at room temperature,easier in developing countries
Ciphands sanitizer
Launched March 2020,in view of #COVIDー19
Indias 1st extrafine ICS-LABA combinatn HFA inhaler,targets drug delivery to small airways affected in 50 to 60% asthma & COPD patients
Quetiapine
Atypical antipsychotic drug for bipolar disorders,major depression & schizophrenia
@Cipla_Global
Received USFDA approval,an AB-rated generic therapeutic capsule for neuropathic pain in Diabetic peripheral neuropathy,postherpetic neuralgia & fibromyalgia
Elores
Acq from Venus remedies, Antibiotic resistance breaker,used in complicated resistant infections
S Africa business grew 8%
US scaled up revenues to $547mn, Albuterol approval,gAdvair filing
API business grew 5% in $terms
Revenues 17132cr
Ebidta 3230cr
Ebidta margin 19%
Net debt from 1581 in fy18/19 to 807cr in 19/20
FCF from 1043cr in fy18/19 to 1955cr in fy19/20
Europe 5
Emerging markets 9
South Africa 18
Global API 4
India 39
North America 23
Others 2
Revenue 16132cr in fy18/19 to 17132cr in fy19/20
Employee expenses stood at 3027cr ,up 6%
Total R&D stood at 1175cr or 6.9% revenue mainly respiratory portfolio
1st generic of proventil HFA(albuterol sulfate)
Targeted at patients 4 yrs & above for reversible obstructive airway disease & exercise induced bronchospasm
Extracts from Cipla AR 2019-20
@Coolfundoo @LongtrmInvests @koppik @punitbansal14 @Cipla_Global
Unroll
@threadreaderapp
Compile
@threader_app
![](https://pbs.twimg.com/media/EgCD4NKU8AAGZEm.jpg)
![](https://pbs.twimg.com/media/EgCD4blUcAAo49r.jpg)